Neuphoria Therapeutics Inc. Share Price
NASDAQ: NEUP | Micro Cap$3.11
+$3.11 (--%) Last updated on 30 Oct, 2026 | 01:19 ISTNeuphoria Therapeutics Inc. Stock Performance
Neuphoria Therapeutics Inc. Share Price Chart
$3.11$3.15
L
H
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Neuphoria Therapeutics Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $3.52 | $3.11 | -12.15% |
Sep 2026 | $3.80 | $3.54 | -6.35% |
Aug 2026 | $3.94 | $3.78 | -3.32% |
Jul 2026 | $4.51 | $3.91 | -11.74% |
Jun 2026 | $5.27 | $4.43 | -15.62% |
May 2026 | $5.29 | $5.25 | -1.50% |
Apr 2026 | $4.21 | $5.33 | +30.96% |
Mar 2026 | $4.33 | $4.07 | -2.63% |
Feb 2026 | $4.02 | $4.18 | +4.76% |
Jan 2026 | $3.88 | $3.99 | +4.45% |
Dec 2025 | $4.43 | $3.82 | -15.11% |
Nov 2025 | $4.53 | $4.50 | -1.10% |